KRMD vs. BLUA, BWAY, ALUR, MGRM, DCTH, STIM, TELA, NVNO, ICCM, and SEPA
Should you be buying KORU Medical Systems stock or one of its competitors? The main competitors of KORU Medical Systems include BlueRiver Acquisition (BLUA), BrainsWay (BWAY), Allurion Technologies (ALUR), Monogram Orthopaedics (MGRM), Delcath Systems (DCTH), Neuronetics (STIM), TELA Bio (TELA), enVVeno Medical (NVNO), IceCure Medical (ICCM), and SEP Acquisition (SEPA). These companies are all part of the "surgical & medical instruments" industry.
KORU Medical Systems (NASDAQ:KRMD) and BlueRiver Acquisition (NYSE:BLUA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
BlueRiver Acquisition has a net margin of 0.00% compared to KORU Medical Systems' net margin of -48.18%. BlueRiver Acquisition's return on equity of 0.00% beat KORU Medical Systems' return on equity.
In the previous week, KORU Medical Systems had 1 more articles in the media than BlueRiver Acquisition. MarketBeat recorded 2 mentions for KORU Medical Systems and 1 mentions for BlueRiver Acquisition. BlueRiver Acquisition's average media sentiment score of 0.00 beat KORU Medical Systems' score of -0.33 indicating that BlueRiver Acquisition is being referred to more favorably in the news media.
BlueRiver Acquisition has lower revenue, but higher earnings than KORU Medical Systems.
58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 22.3% of BlueRiver Acquisition shares are owned by institutional investors. 25.6% of KORU Medical Systems shares are owned by company insiders. Comparatively, 79.0% of BlueRiver Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
KORU Medical Systems presently has a consensus target price of $3.50, indicating a potential upside of 59.09%. Given KORU Medical Systems' higher probable upside, equities research analysts clearly believe KORU Medical Systems is more favorable than BlueRiver Acquisition.
KORU Medical Systems received 36 more outperform votes than BlueRiver Acquisition when rated by MarketBeat users.
Summary
KORU Medical Systems beats BlueRiver Acquisition on 7 of the 12 factors compared between the two stocks.
Get KORU Medical Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KORU Medical Systems Competitors List
Related Companies and Tools
